This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Amicus Therapeutics Introduces Proprietary "CHART" Platform Technology

CRANBURY, N.J., March 4, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), today introduced Ch aperone- A dvanced R eplacement T herapy (CHART™) as the brand name for its technology platform that combines unique pharmacological chaperones with enzyme replacement therapy (ERT) for lysosomal storage diseases.

John F. Crowley, Chairman and Chief Executive Officer of Amicus stated, "We are pleased to introduce CHART as the brand name and designation for our chaperone-ERT combination platform. CHART reflects the breadth of the opportunities at Amicus to develop chaperones co-administered with marketed ERTs, or co-formulated with proprietary enzymes as next-generation ERTs. It is a platform that has already demonstrated proof of concept in the clinic and in multiple pre-clinical studies. The direct co-formulation of our proprietary enzymes with specific small molecule chaperone stabilizers may improve treatment outcomes, reduce immunological responses and potentially enable more convenient delivery routes with these next-generation ERTs. Our strategic vision is to build out this CHART platform to deliver new benefits for patients and create multiple sources of value for our shareholders. This platform will indeed chart a course to a very bright future for Amicus."

Ch aperone- Advanced Replacement Therapy (CHART)

Amicus is leveraging the CHART platform to improve currently marketed ERTs through co-administration of a pharmacological chaperone prior to ERT infusion, and to develop next-generation ERTs that consist of proprietary lysosomal enzyme therapies co-formulated with pharmacological chaperones.

ERTs are the standard of care for many lysosomal storage diseases. A recombinant or gene-activated human enzyme is manufactured for intravenous infusion into the circulation for transport to the lysosome. Once in lysosomes, ERT can perform the function of a person's own missing or deficient enzyme. However, these therapeutic enzymes may unfold and lose activity at any stage in the process, from the infusion bag to the bloodstream to the eventual uptake into cells and tissue. This instability, unfolding, and loss of enzyme activity may impact treatment outcomes with ERT.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG

Markets

DOW 18,285.74 +0.34 0.00%
S&P 500 2,130.82 +4.97 0.23%
NASDAQ 5,090.7940 +19.0510 0.38%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs